Infosys Limited
$50.55B- Market cap
- $47.45B
- Debt
- +$5.96B
- Cash
- −$2.86B
Capital structure 89% equity / 11% debt · EV / Revenue 2.62x · EV / EBITDA 15.99x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $47.45B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 ·
Decision snapshot: INFY stock price vs CRSP: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CRSP's multiple
Needs CRSP P/E.
Implied fair value · at INFY's multiple
Needs EPS (TTM) is negative, INFY P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INFY FY 2025 (ended Mar 31, 2025) · CRSP FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 89% equity / 11% debt · EV / Revenue 2.62x · EV / EBITDA 15.99x
Capital structure 96% equity / 4% debt · EV / Revenue 1030.21x
INFY carries the larger enterprise value at $50.55B against $3.62B; INFY trades on the lower EV / Revenue multiple (2.62x vs 1030.21x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
INFOSYS LIMITED · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
CRISPR THERAPEUTICS AG · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
—
0.10x
Net debt / EBITDA
Leverage against operating earnings
0.98x
3.18x
Cash and equivalents
Liquid reserves on the balance sheet
$2.86B
$1.98B
Total debt
Interest-bearing obligations outstanding
$5.96B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$197.39M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.